SEC Form SC 13G/A filed by Heartbeam Inc. (Amendment)

$BEAT
Medical/Dental Instruments
Health Care
Get the next $BEAT alert in real time by email
SC 13G/A 1 g083404_sc-13ga.htm SC 13G/A

 

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

 

HeartBeam, Inc.

(Name of Issuer)

 

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

 

42238H108

(CUSIP Number)

 

December 31, 2022

(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

CUSIP No. 42238H108

  13G   Page 2 of 9 Pages
   
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Ionic Ventures, LLC
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    
(b)    
3. SEC USE ONLY
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION
 
California, United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5. SOLE VOTING POWER
 
0
6.

SHARED VOTING POWER

 

41,519 (1)

7. SOLE DISPOSITIVE POWER
 
0
8.

SHARED DISPOSITIVE POWER

 

41,519 (1)

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

41,519 (1)
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.52%
12. TYPE OF REPORTING PERSON (see instructions)

OO
(1)As more fully described in Item 4, the number of shares beneficially owned consists of 41,519 shares of Common Stock to be issued upon the exercise of shares of Warrants held by the Reporting Persons.

 

 

 

 

CUSIP No. 42238H108   13G   Page 3 of 9 Pages
   
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Brendan O’Neil
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    
(b)    
3. SEC USE ONLY
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5. SOLE VOTING POWER
 
0
6. SHARED VOTING POWER
 
41,519 (1)
7. SOLE DISPOSITIVE POWER
 
0
8. SHARED DISPOSITIVE POWER
 
41,519 (1)

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

41,519 (1)
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.52%
12. TYPE OF REPORTING PERSON (see instructions)

IN
(1)As more fully described in Item 4, the number of shares beneficially owned consists of 41,519 shares of Common Stock to be issued upon the exercise of shares of Warrants held by the Reporting Persons.

 

 

 

 

CUSIP No. 42238H108   13G   Page 4 of 9 Pages
   
1. NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

Keith Coulston
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    
(b)    
3. SEC USE ONLY
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5. SOLE VOTING POWER
 
0
6. SHARED VOTING POWER
 
41,519 (1)
7. SOLE DISPOSITIVE POWER
 
0
8. SHARED DISPOSITIVE POWER
 
41,519 (1)

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

41,519 (1)
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

0.52%
12. TYPE OF REPORTING PERSON (see instructions)

IN
(1)As more fully described in Item 4, the number of shares beneficially owned consists of 41,519 shares of Common Stock to be issued upon the exercise of shares of Warrants held by the Reporting Persons.

 

 

 

 

CUSIP No. 42238H108   13G   Page 5 of 9 Pages

 

Item 1(a). Name of Issuer:

 

HeartBeam, Inc. (the “Issuer”).

 

Item 1(b). Address of Issuer’s Principal Executive Offices:

 

The Issuer’s principal executive offices are located at 2118 Walsh Ave., Suite 210, Santa Clara, CA 95050.

 

Item 2(a). Names of Persons Filing:

 

This statement is filed by:
   
  (i) Ionic Ventures LLC, a California limited liability company (“Ionic”);
   
  (ii) Brendan O’Neil (“Mr. O’Neil”); and
   
  (iii)  Keith Coulston (“Mr. Coulston”).

 

The foregoing persons are hereinafter sometimes collectively referred to as the (“Reporting Persons”). Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

 

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

 

The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.  

 

Item 2(b). Address of Principal Business Office or, if none, Residence:

 

The principal business address of each of the Reporting Persons is 3053 Fillmore St, Suite 256, San Francisco, CA 94123.

 

Item 2(c). Citizenship:

 

Ionic is a limited liability company organized under the laws of California. Each of Mr. O’Neil and Mr. Coulston is a citizen of the United States.

 

Item 2(d). Title of Class of Securities:

 

The title of the class of securities to which this statement relates is Common Stock, par value $0.0001 per share.

 

Item 2(e). CUSIP Number:

 

42238H108

 

 

 

 

CUSIP No. 42238H108   13G   Page 6 of 9 Pages

 

Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

 

Not applicable.

 

Item 4. Ownership.

 

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on (i) 8,009,743 shares of Common Stock outstanding as of December 31, 2022 as reported in the Issuer’s Registration Statement on Form S-3 filed with the U.S. Securities and Exchange Commission on February 2, 2023 and (ii) 41,519 shares of Common Stock that are issuable upon exercise of the warrants (the “Warrants”) that are held by the Reporting Persons.

 

As of December 31, 2022, the Reporting Persons hold 41,519 shares of Common Stock issuable upon full exercise of the Warrants held by the Reporting Persons.

 

As of December 31, 2022, Ionic is the beneficial owner of 41,519 shares of Common Stock (the “Shares”). Ionic has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by its managers, Mr. O’Neil and Mr. Coulston. Mr. O’Neil and Mr. Coulston, as managers of Ionic, have shared power to vote and/or dispose of the Shares beneficially owned by Ionic. Neither Mr. O’Neil nor Mr. Coulston directly owns any Common Stock of the Issuer. By reason of the provisions of Rule 13d-3 of the Act, each of Mr. O’Neil and Mr. Coulston may be deemed to beneficially own the Shares beneficially owned by Ionic.

 

Item 5. Ownership of Five Percent or Less of a Class.

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following .

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

 

 

 

CUSIP No. 42238H108   13G   Page 7 of 9 Pages

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8. Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9. Notice of Dissolution of Group.

 

Not applicable.

 

Item 10. Certification.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 

 

 

 

CUSIP No. 42238H108   13G   Page 8 of 9 Pages

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 13, 2023 IONIC VENTURES, LLC
   
  /s/ Keith Coulston
  Name: Keith Coulston
  Title: Partner
   
  /s/ Brendan O’Neil
  Brendan O’Neil
   
  /s/ Keith Coulston
  Keith Coulston

 

 

 

 

CUSIP No. 42238H108   13G   Page 9 of 9 Pages

 

EXHIBIT 1

 

JOINT FILING AGREEMENT

PURSUANT TO RULE 13d-1(k)

 

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. The undersigned hereby further agree that this Joint Filing Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original, but all of which counterparts shall together constitute one and the same instrument.

 

Date: February 13, 2023 IONIC VENTURES, LLC
   
  /s/ Keith Coulston
  Name: Keith Coulston
  Title: Partner
   
  /s/ Brendan O’Neil
  Brendan O’Neil
   
  /s/ Keith Coulston
  Keith Coulston

 

 

Get the next $BEAT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BEAT

DatePrice TargetRatingAnalyst
12/20/2021$9.00Speculative Buy
Benchmark
More analyst ratings

$BEAT
Press Releases

Fastest customizable press release news feed in the world

See more
  • HeartBeam Reports Fourth Quarter and Full Year 2024 Results

    Received FDA Clearance for the HeartBeam System – an At-Home, High-Fidelity Heart Monitoring Technology Commenced Early Access Program to Attain Key Insights and Establish Sales Funnel in Preparation for Commercialization Submitted 510(k) Application to FDA for Groundbreaking 12-lead Electrocardiogram (ECG) Synthesis Software Gross Proceeds of ~$11.5 Million from Public Offering and Over-Allotment Option to Fund Near-Term Milestones Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, has reported its financial and operation

    $BEAT
    Medical/Dental Instruments
    Health Care
  • HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that CEO Robert Eno and CFO Timothy Cruickshank will be participating in the following upcoming conferences in Dana Point, CA. 37th Annual Roth Conference being held at The Laguna Cliffs Marriott Resort & Spa, March 16-18, 2025 LSI USA '25 Conference being held at the Waldorf Astoria, Monarch Beach, March 17-21, 2025 To schedule a one-on-one meeting with HeartBeam management, please contact your conference representative or email your request to BEAT@mzgroup.us or call Chris Tyson at (949) 491-8235. About HeartBeam, Inc. HeartB

    $BEAT
    Medical/Dental Instruments
    Health Care
  • HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

    $BEAT
    Medical/Dental Instruments
    Health Care

$BEAT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BEAT
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BEAT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BEAT
SEC Filings

See more

$BEAT
Leadership Updates

Live Leadership Updates

See more
  • HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

    First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

    $BEAT
    Medical/Dental Instruments
    Health Care
  • HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

    Industry leader brings extensive experience in developing go-to-market strategies for breakthrough products and delivering growth Founder and current CEO Branislav Vajdic named President to focus on advancing the Company's groundbreaking vector-based technology for heart health, including AI applications HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful insights wherever the patient is, announced that Robert Eno has been appointed Chief Executive Officer (CEO), effective Monday, October 21, 2024. The seasoned MedTech executive joined HeartBeam as President in January 2023 and will lead as the Company continues to work

    $BEAT
    Medical/Dental Instruments
    Health Care
  • HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist

    Industry Leader, Former Head of Data Science at Verily (Google Life Sciences) and Globally Respected Authority on Artificial Intelligence (AI) Applications in Biosensor Technologies Dr. Myers to Drive Innovation and Strategic Growth as HeartBeam Advances and Expands its AI Capabilities HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, announced the appointment of Lance Myers, PhD, a pioneer in digital health data analytics and body-worn biosensor technologies, as Chief Artificial Intelligence (AI) Scientist. In this newly created position, Dr. Myers will play a pivotal role in gu

    $BEAT
    Medical/Dental Instruments
    Health Care

$BEAT
Financials

Live finance-specific insights

See more
  • HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, will hold a conference call on Thursday, March 13, 2025 at 4:30 p.m. Eastern time to discuss its results for the fourth quarter and full year ended December 31, 2024, and will be providing updates on regulatory initiatives, commercial-readiness activities and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompanied by a presentation, which can be

    $BEAT
    Medical/Dental Instruments
    Health Care
  • HeartBeam Reports Third Quarter 2024 Results

    Continued Clinical and Regulatory Progress on the HeartBeam System Key Appointments to Management Team Completed as Part of Planned Evolution in Preparation for US Commercialization Strengthening Clinical Evidence Base, with Two Additional Studies to be Presented at the American Heart Association Conference in November 2024 Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported its financial and operational results for the third quarter ended September 30, 2024. Third Quarter & Subsequent 2024 Operational Highlights

    $BEAT
    Medical/Dental Instruments
    Health Care
  • HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights wherever the patient is, will hold a conference call on Thursday, November 7, 2024 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2024, and will be providing regulatory updates, reviewing ongoing initiatives, and anticipated milestones. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno, Founder and President Branislav Vajdic, PhD, and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The conference call will be accompa

    $BEAT
    Medical/Dental Instruments
    Health Care

$BEAT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more